Antimicrobial and anticancer lipopeptides
Lipophilic conjugates comprise a peptide coupled to a fatty acid The peptide comprises at least two positively charged amino acid residues; the peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by pathogenic organisms such as bacteria and fungi. The lipophilic conjugates are also suitable for sanitation, as disinfectants, or for food preservation.
1. A lipophilic conjugate comprising a peptide coupled to a fatty acid, the peptide or a salt thereof consisting of 2 to 14 amino acid residues having a net positive charge that is equal or greater than +1 comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid having at least one activity selected from the group consisting of antibacterial, antifungal, and anticancer activity, wherein the activity after conjugation being higher than prior to conjugation, the peptide prior to conjugation of said fatty acid being devoid of or having very weak antibacterial and antifungal activity, wherein the lipophilic conjugate is selected from the group of lipopeptides set forth in SEQ ID NOS: 1 to 38.
2. A method for treating a bacterial or fungal infection in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a carrier and, as an active ingredient, a lipophilic conjugate according to claim 1 .
3. The method according to claim 2 , wherein administering the pharmaceutical composition to the subject is selected from topical, intravenous, intraarterial, intramuscular, intraperitoneal, oral, ophthalmic, nasal, vaginal, rectal, and intralesional administration.
4. The method according to claim 3 , wherein administering the pharmaceutical composition is by topical administration.
5. The method according to claim 2 , wherein the infection is a bacterial infection.
6. The method according to claim 5 , wherein the bacterial infection is caused by antibiotic-resistant bacteria.
7. The method according to claim 6 , wherein the antibiotic-resistant bacteria are selected from Streptococcus pyogenes and Staphylococcus aureus.
8. The method according to claim 2 , wherein the infection is a fungal infection.
9. The method according to claim 2 , wherein the subject has acne, poorly healing skin lesions, or burn wounds or the infection is selected from fungal infections of the scalp, fungal infections related to traumatic wounds, bacterial infections related to traumatic wounds, and bacterial or fungal eye or ear infections.
10. A method for treating prostate cancer in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a lipophilic conjugate according to claim 1 .
11. The method according to claim 10 , wherein the administering of the pharmaceutical composition is into the prostate or adjacent to the prostate.
12. A method for reducing bacterial or fungal growth on an object comprising contacting the object with a composition comprising as an active ingredient a lipophilic conjugate according to claim 1 .
13. The method according to claim 12 , wherein the object is selected from the group consisting of tissue culture equipment, tissue culture media, tissue culture incubators, tissue culture hoods, and tissue culture dishes.
14. The method according to claim 12 , wherein the object is selected from medical and surgical equipment.